Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)
| Autor: | Carmen Roncal, Josune Orbe, Amaia Vilas-Zornoza, Núria Planell, David Lara-Astiaso, Felipe Prosper, Esther Martinez-Aguilar, Goren Saenz-Pipaon, Alberto Maillo, David Gomez-Cabrero, Patxi San Martin, Daniel Alameda, Susana Ravassa, José A. Páramo, José Antonio Rodriguez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Histology Arterial disease peripheral artery disease Extracellular vesicles liquid-biopsy Liquid-biopsy Transcriptome 03 medical and health sciences 0302 clinical medicine medicine RNA-Seq Liquid biopsy lcsh:QH573-671 thrombosis Peripheral artery disease business.industry lcsh:Cytology Thrombosis Cell Biology medicine.disease Peripheral 030104 developmental biology rna-seq 030220 oncology & carcinogenesis Calprotectin business extracellular vesicles Research Article |
| Zdroj: | Journal of Extracellular Vesicles, Vol 9, Iss 1 (2020) Journal of Extracellular Vesicles |
| Popis: | Peripheral arterial disease (PAD) is associated with a high risk of cardiovascular events and death and is postulated to be a critical socioeconomic cost in the future. Extracellular vesicles (EVs) have emerged as potential candidates for new biomarker discovery related to their protein and nucleic acid cargo. In search of new prognostic and therapeutic targets in PAD, we determined the prothrombotic activity, the cellular origin and the transcriptomic profile of circulating EVs. This prospective study included control and PAD patients. Coagulation time (Procoag-PPL kit), EVs cellular origin and phosphatidylserine exposure were determined by flow cytometry in platelet-free plasma (n = 45 PAD). Transcriptomic profiles of medium/large EVs were generated using the MARS-Seq RNA-Seq protocol (n = 12/group). The serum concentration of the differentially expressed gene S100A9, in serum calprotectin (S100A8/A9), was validated by ELISA in control (n = 100) and PAD patients (n = 317). S100A9 was also determined in EVs and tissues of human atherosclerotic plaques (n = 3). Circulating EVs of PAD patients were mainly of platelet origin, predominantly Annexin V positive and were associated with the procoagulant activity of platelet-free plasma. Transcriptomic analysis of EVs identified 15 differentially expressed genes. Among them, serum calprotectin was elevated in PAD patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|